CEO
Terns Pharmaceuticals, Inc.
Board Member
Terns Pharmaceuticals, Inc.
Board Member
Tenaya Therapeutics, Inc. (TNYA)Equibles does not estimate personal net worth.
Amy Burroughs is recorded as Board Member at Terns Pharmaceuticals, Inc. since January 1, 2024, CEO at Terns Pharmaceuticals, Inc. and Board Member at Tenaya Therapeutics, Inc. (TNYA) since January 1, 2022. The newest filing on record that lists Amy Burroughs as CEO and Board Member at Terns Pharmaceuticals, Inc. is dated April 29, 2025. The newest filing on record that lists Amy Burroughs as Board Member at Tenaya Therapeutics, Inc. (TNYA) is dated April 16, 2026. Earlier roles on record: Board Member at DiaMedica Therapeutics Inc. (DMAC) until March 1, 2023. Tenaya Therapeutics, Inc. reported in an 8-K filed May 29, 2026 that Amy Burroughs was appointed Class II Director, effective May 27, 2026. Terns Pharmaceuticals, Inc. reported in an 8-K filed February 7, 2024 that Amy Burroughs was appointed member of the Board of Directors, effective February 7, 2024. Terns Pharmaceuticals, Inc. reported in an 8-K filed February 7, 2024 that Amy Burroughs was appointed Chief Executive Officer, effective February 7, 2024. Equibles holds 5 filed executive changes naming Amy Burroughs; each is listed under recent activity with its source filing. The proxy statement of Terns Pharmaceuticals, Inc. reports total compensation of $8,240,502 for Amy Burroughs in fiscal 2024, including a base salary of $563,701. Amy Burroughs has spoken on 1 investor event across 1 company, most recently for Terns Pharmaceuticals, Inc. on March 2, 2026. Terns Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Tenaya Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tenaya Therapeutics, Inc. includes Faraz Ali (CEO, CFO and Board Member), Eric Hyllengren (CFO), Chihiro Saito (Chief Accounting Officer) and 7 others.
“Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
“has been appointed and elected as a member of the Board of Directors of Terns (the "Board"), effective as of February 7, 2024 (the "Effective Date").”
“And thanks again, Yaron, for having us and to the TD Cowan team. I will also say that we will be making forward-looking statements and to refer to our website and our filings for more information.”
Terns Pharmaceuticals, Inc.
Board Member
Proxy statement
2024-01-01–present
Last confirmed April 29, 2025
2022-01-01–present
Last confirmed April 16, 2026
Terns Pharmaceuticals, Inc.
CEO
Proxy statement
Start not stated–present
Last confirmed April 29, 2025
Start not stated–2023-03-01
Terns Pharmaceuticals, Inc.
Biotechnology · Healthcare
CEO, Board Member
2024-01-01–present
Biotechnology · Healthcare
Board Member
2022-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Terns Pharmaceuticals, Inc. | M.B.A. Chief Executive Officer and Director | $563,701 | $8,240,502 |
TD Cowen 46th Annual Health Care Conference
Terns Pharmaceuticals, Inc.
